Summary and conclusions A total of 466 healthy adults from four different regions of England entered a double-blind, randomised trial to test the effectiveness of an antihistamine (triprolidine) and a decongestant (pseudoephedrine), alone or in combination, in relieving symptoms of the common cold. During the study 199 subjects reported a total of 243 colds. Subjects recorded the severity of 12 symptoms during treatment and noted separately the severity of a further seven symptoms that represented unwanted effects of treatment or served as an index of suggestibility. They were then asked about their overall improvement in symptoms during treatment and whether they thought they had taken placebo.
Introduction
The common cold cannot yet be prevented so doctors and patients have to be satisfied with whatever they think lessens the misery of its symptoms. The popular supposition that concurrent treatment with an antihistamine and a decongestant provides some relief of symptoms is reflected by the vast consumption of proprietary formulations of this kind. Yet wellconducted studies have not shown any benefit from such treatment, at least with antihistamines.' We therefore examined the effects of a decongestant and antihistamine combination in a study using only subjective criteria. We argued that although the range of symptoms of the common cold was wide, the symptoms in any one person were probably fairly constant, so that each person might thus be regarded as an expert on his or her own symptoms. Their opinions on the effects of a treatment on wellbeing should be conclusive even when the components of that feeling cannot be fully analysed and measured. We attempted to see whether symptoms of the common cold were influenced differently by treatment with an antihistamine (triprolidine) and a decongestant (pseudoephedrine) separately and in combination, or by a dummy treatment.
Subjects and methods
A panel of 466 healthy volunteers was enrolled before the trial period from the staff of the Wellcome Foundation in four different regions in England. From 1 October 1976 to 31 March 1977 people had one cold, 36 had two colds, seven had three colds, and one had four colds, making a total of 243 colds. After developing a cold all subjects were interviewed by a nursing sister, who admitted them to the study subject to compliance with entry criteria designed to ensure regional conformity and to exclude volunteers taking medicines that could interfere with the study. An interview questionnaire was later used to check for homogeneity within the treatment groups for age, sex, usual number of colds each winter, absence of allergic disorders, smoking habits, duration of symptoms, and signs of fever.
Drugs were allocated from separate randomisation lists for men and women aged below and above 40 years and at each centre (16 lists in all). Balance in numbers was arranged after every eighth person in each list. The treatments administered were as follows: placebo, 63 courses; pseudoephedrine hydrochloride 60 mg, 63 courses; triprolidine hydrochloride 2-5 mg, 61 courses; and pseudoephedrine 60 mg and triprolidine 2-5 mg, 56 courses. Drugs were issued to patients in coded bottles containing 20 tablets with instructions to take one tablet three times daily for as long as they thought necessary. All tablets were identical in appearance. All were specially made and differed in appearance from marketed preparations.
Volunteers had to mark for severity using a four-point scale 12 symptoms relating to the common cold on a daily diary card. The 12 symptoms were those most often mentioned in a preliminary poll taken in two of the four regions. The volunteers also had to mark for severity in a separate daily diary seven symptoms, four of which were possible unwanted effects of treatment (palpitations, sleeplessness, drowsiness, and dry mouth) and three unlikely effects that provided an index of suggestibility. Finally, on the eighth to tenth day they were asked by a nursing sister standardised questions about their overall impression of improvement in symptoms while taking tablets and also specifically, "Do you think the trial tablets you took were the placebo ?" Symptom scores and other numerical data were analysed by the x2 test. The significance level was p<005 except when comparison of the four treatments showed a significant difference, when individual comparisons in pairs were made with the significance level at p < 0-01. The treatment groups were homogeneous so far as could be ascertained. The mean age (±SD) of the 243 subjects was 30-9±10 years. The mean numbers of tablets consumed in each treatment group ranged from 19-6 to 15-0.
Results
Symptoms-Diaries were completed for 60 courses of dummy, 61 of pseudoephedrine, 59 of triprolidine, and 55 of pseudoephedrine plus triprolidine. The average duration of symptoms (±SD) before presentation was 20-7±17-7 h (n=230). The overall incidence of the specified symptoms was "cold in the head," 95%; running nose, 88%; sneezing, 84%; blocked nose, 80%; sore throat, 77%; headache, 73%; cough, 72%; feeling ill, 69%; phlegm, 63%; hoarseness, 59%; ache in back or limbs, 47%; and feeling feverish, 40%. The sneezing score was significantly reduced when the combination tablet was taken compared with placebo on days 2, 3, and 4 of the cold. It was also significantly reduced by pseudoephedrine on days 2 and 3 and by triprolidine on day 2 when compared with placebo. Nasal obstruction, like sneezing, was worst early on in the cold and was significantly improved when assessed as a change from baseline on day 1 only when pseudoephedrine or the combination tablet was taken. The other specific symptoms were not significantly affected by the treatments.
Unwanted effects-Of the seven listed unwanted effects, difficulty in sleeping was reported by 25 volunteers who took pseudoephedrine and nine who took placebo. This difference was significant. The number reporting all types of unwanted effects was greatest in the group given placebo (table I). Three stopped taking tablets (and completing the diary) because of unwanted effects-two because of excessive drowsiness while taking triprolidine and one because urticaria developed during treatment with pseudoephedrine. No reasons were obtained from the other volunteers who did not complete diaries. The incidence of drug-related symptoms that were unlikely was low at entry to the trial and did not increase appreciably during it.
Final questionnaire- Table II shows the responses to the question, "After taking the trial tablets did your cold symptoms improve, worsen, or remain unchanged ?" Both pseudoephedrine and the combination tablet improved the symptoms in significantly more volunteers than did the placebo. Table I shows the numbers of replies to the question, "Were the trial tablets placebo ?" These are classified according to the drug taken, the subjects' final assessment of benefit (see table II), and the discernment of unwanted effects as reported on the diary cards. Most of those not attributing benefit to the tablets thought they had taken placebo both when this was true and when it was false. Few of those attributing benefit to the tablets thought these were placebo even when they were. Most ofthe unwanted effects reported in the daily diaries occurred in volunteers who at the end of the study did not attribute benefit to the tablets; they were uncommon among those who believed that the tablets had helped them.
Discussion
Sneezing and nasal obstruction were the only symptoms specifically modified by each of the treatments, but these were the two most likely to be improved by the known pharmacological action of the drugs. Analysis of the responses of the other symptoms did not explain more comprehensively why the volunteers considered the combination of an antihistamine and a sympathomimetic, or a sympathomimetic alone, as having a general beneficial effect. An overall subjective assessment of benefit is valid so long as the study is double blind and the subjects cannot recognise the active drugs from the perception of other, unwanted, effects. Table I clearly shows that they did not; more people attributed unwanted effects to placebo than to any of the active drugs. It is not surprising that those who thought that they did not benefit from the drugs also thought that they had taken placebo, because these two questions were asked at the same time at the end of the study. Interestingly, however, the incidence of reported unwanted effects was high in the "not improved" group. The unwanted effects were reported daily and the volunteers did not know that they would be asked at the end of the study to guess whether they had taken an active drug or a placebo. The large number who reported unwanted effects when taking placebo, and who decided at the end of the study that they had taken placebo, shows the lack of association between drug recognition and the reporting of unwanted effects.
Apparently, unwanted effects were attributed to any tablets (active or otherwise) from which the volunteers did not detect any benefit. On the other hand, relatively few who thought that they were being helped by the treatment reported unwanted effects, even when taking active drugs. This observation may have implications for recognising unwanted effects when patients notice an improvement in symptoms during treatment.
Our study shows that a significant majority of the volunteers benefited from pseudoephedrine and the combination of pseudoephedrine and triprolidine, and nearly half also did so with triprolidine alone, although this did not reach the significance level (p <0-01) required for subjective data. Apart from sneezing and nasal obstruction, the symptoms whose relief produced this benefit could not always be identified and were presumably not definable by the subjects.
